AIM ImmunoTech reports mid-year update from Phase 2 study of Aimpligen, Imfinzi

AIM ImmunoTech (AIM) reported positive data in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX. The DURIPANC study – which is a joint collaboration with AstraZeneca and Erasmus Medical Center in the Netherlands – is an investigator-initiated, exploratory, open-label, single-center study expected to enroll up to 25 subjects in the Phase 2 portion. Compared to these data, the DURIPANC study mid-year report shows continuing promising early signs of both no significant toxicity and superior PFS and OS: No significant toxicity, an encouraging safety profile for a post-chemo setting; ~21% of patients have PFS greater than6 months, with an additional 21% not yet progressed; and OS greater than6 months in the majority of eligible patients-better than expected in this setting.